← Back to patent-cliff list
Sultiame
Tier C — Watch / tradeSultiame
-
Originator
2001
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CA2
Brand：Ospolot
Indications (approved)：Epilepsy
Regional status
US
-
EU
Phase II
2021-11-23
China
-
Japan
Approved
2001-12-01
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sultiame?
Approved indications include: Epilepsy.
When does the Sultiame patent expire?
No public expiry year is available for Sultiame yet; this page updates once verified.
How do I get a quote for Sultiame intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27